Chemotherapy Resistance as a Predictor of Progression-Free Survival in Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy and Surgical Cytoreduction Followed by Intraperitoneal Chemotherapy: A Southwest Oncology Group Study | Zendy

Amy Tiersten | Zendy; James Moon | Zendy; Harriet O. Smith | Zendy; Sharon P. Wilczynski | Zendy; rd William R. Robinson | Zendy; Maurie Markman | Zendy; David S. Alberts | Zendy

Open Access

Chemotherapy Resistance as a Predictor of Progression-Free Survival in Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy and Surgical Cytoreduction Followed by Intraperitoneal Chemotherapy: A Southwest Oncology Group Study

Author(s) -

Amy Tiersten,

James Moon,

Harriet O. Smith,

Sharon P. Wilczynski,

rd William R. Robinson,

Maurie Markman,

David S. Alberts

Publication year - 2009

Publication title -

oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.987

H-Index - 98

eISSN - 1423-0232

pISSN - 0030-2414

DOI - 10.1159/000279386

Subject(s) - medicine , carboplatin , debulking , oncology , ovarian cancer , chemotherapy , paclitaxel , cancer , clinical trial , gynecologic oncology , surgery , cisplatin

In vitro testing of the activity of chemotherapeutic agents has been suggested as 1 method to optimally select drugs for patients with ovarian cancer. There are limited prospectively obtained data examining the clinical utility of this approach. We sought to obtain a preliminary assessment of this strategy in a trial that examined the administration of neoadjuvant chemotherapy followed by surgical cytoreduction and intraperitoneal chemotherapy in women with advanced ovarian cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research